JP2008536483A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536483A5
JP2008536483A5 JP2008500259A JP2008500259A JP2008536483A5 JP 2008536483 A5 JP2008536483 A5 JP 2008536483A5 JP 2008500259 A JP2008500259 A JP 2008500259A JP 2008500259 A JP2008500259 A JP 2008500259A JP 2008536483 A5 JP2008536483 A5 JP 2008536483A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
nucleic acid
acid molecule
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008500259A
Other languages
English (en)
Japanese (ja)
Other versions
JP4933527B2 (ja
JP2008536483A (ja
Filing date
Publication date
Priority claimed from GBGB0504767.5A external-priority patent/GB0504767D0/en
Application filed filed Critical
Publication of JP2008536483A publication Critical patent/JP2008536483A/ja
Publication of JP2008536483A5 publication Critical patent/JP2008536483A5/ja
Application granted granted Critical
Publication of JP4933527B2 publication Critical patent/JP4933527B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008500259A 2005-03-08 2006-03-08 リポカリンタンパク質 Expired - Fee Related JP4933527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0504767.5A GB0504767D0 (en) 2005-03-08 2005-03-08 Lipocalin protein
GB0504767.5 2005-03-08
PCT/GB2006/000820 WO2006095164A1 (en) 2005-03-08 2006-03-08 Lipocalin protein

Publications (3)

Publication Number Publication Date
JP2008536483A JP2008536483A (ja) 2008-09-11
JP2008536483A5 true JP2008536483A5 (enExample) 2009-04-30
JP4933527B2 JP4933527B2 (ja) 2012-05-16

Family

ID=34452020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008500259A Expired - Fee Related JP4933527B2 (ja) 2005-03-08 2006-03-08 リポカリンタンパク質

Country Status (15)

Country Link
US (1) US20080254035A1 (enExample)
EP (1) EP1869074A1 (enExample)
JP (1) JP4933527B2 (enExample)
KR (1) KR20070118614A (enExample)
CN (1) CN101189257A (enExample)
AU (1) AU2006221859B2 (enExample)
BR (1) BRPI0609020A2 (enExample)
CA (1) CA2599540A1 (enExample)
EA (1) EA011816B1 (enExample)
GB (1) GB0504767D0 (enExample)
IL (1) IL185547A0 (enExample)
MX (1) MX2007010809A (enExample)
NO (1) NO20075068L (enExample)
UA (1) UA94221C2 (enExample)
WO (1) WO2006095164A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877428B1 (en) 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
JP5858932B2 (ja) 2010-02-04 2016-02-10 モルフォテック, インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
AU2011290751B2 (en) * 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
IN2014MN02293A (enExample) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
SG11201504600UA (en) * 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
ES2786253T3 (es) 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US20160250258A1 (en) 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
EP3102224B1 (en) * 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
JP5866053B1 (ja) * 2014-12-15 2016-02-17 株式会社ファンケル 皮膚粘弾性のマーカー及びその利用
EP4177336A1 (en) 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
CA3084551A1 (en) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
WO2020227475A1 (en) 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cll-1 targeted immunotherapies
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
CN111979249B (zh) * 2020-07-28 2021-12-10 复旦大学附属眼耳鼻喉科医院 一种特异性结合脂质运载蛋白-1的核酸适配体及其应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701453A (ko) * 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5362865A (en) * 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) * 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20020137159A1 (en) * 2000-08-31 2002-09-26 Si Lok Human phermone polypeptides

Similar Documents

Publication Publication Date Title
JP2009268467A5 (enExample)
JP2023506765A5 (enExample)
JP2008529558A5 (enExample)
JP2018506286A5 (enExample)
ES2612741T3 (es) Proteínas de fusión proteína n de un virus de la familia paramyxoviridae-proteína de interés
JP2008508859A5 (enExample)
JP2010529860A5 (enExample)
JP2018510622A5 (enExample)
JP2011528896A5 (enExample)
JP2012505902A5 (enExample)
JP2008507298A5 (enExample)
JP2006502702A5 (enExample)
JP2023528204A5 (enExample)
JP2025170319A (ja) Sars-cov-2阻害剤
JP2011501950A5 (enExample)
CN113201051B (zh) 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
CN116693673B (zh) 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用
JP2012516140A5 (enExample)
JP2007535910A5 (enExample)
JP2014504297A5 (enExample)
CN115746148A (zh) 具有冠状病毒rbd和膜融合抑制多肽的蛋白质及其作为冠状病毒抑制剂的应用
WO2022152204A1 (zh) 一种人乳头瘤病毒病毒样颗粒疫苗的稳定制剂
CN102690327A (zh) 肠道病毒71型的中和表位多肽及其用途
JP2020509770A5 (enExample)
JP2002539781A5 (enExample)